System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42312436 DOI: 10.1021/acs.jmedchem.6c00697

Dual-Acting Vitamin B 3-Melanostatin Neuropeptide Hybrids as Potent Modulators of the Dopamine D 2 Receptors with Neuroprotective Activity.

J Med Chem

Authors: Beatriz L Pires-Lima, Sara C Silva-Reis, Xavier Cruz Correia, Hugo F Costa-Almeida, Vera M Costa, Xerardo García-Mera, José Brea, María I Loza, Marialessandra Contino, Maria Grazia Perrone, Giovanni Graziano, Nuno Vale, José E Rodríguez-Borges, Ivo E Sampaio-Dias

Affiliations

  • LAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal. PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Porto 4200-319, Portugal.
  • LAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal. UCIBIO, REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto 4050-313, Portugal.
  • LAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal.
  • UCIBIO, REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto 4050-313, Portugal.
  • Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto 4050-313, Portugal.
  • Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela E-15782, Spain.
  • Innopharma Screening Platform. Biofarma Research Group. Centre of Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela E-15782, Spain.
  • Department of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, Bari 70125, Italy.
  • PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Porto 4200-319, Portugal.
  • RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Porto 4200-450, Portugal.
  • Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Porto 4200-450, Portugal.

Abstract

Parkinson's disease (PD) therapy remains limited by complications of the levodopa regimen, highlighting the need for novel therapeutic strategies to modulate dopaminergic signaling. Melanostatin (MIF-1) has attracted attention as a privileged scaffold for dopamine D 2 receptor (D 2R) modulation due to its intrinsic positive allosteric modulatory activity, although improved potency and drug-like properties are required for translation. In this work, nicotinic acid (Nic), a vitamer of vitamin B 3, was employed as a proline (Pro) bioisostere, generating 12 vitamin B 3-MIF-1 hybrids. Nicotinoyl-l-leucylglycinamide (6c) emerged as a lead compound, promoting a 5.11-fold enhancement of dopamine potency at 0.01 nM and displaying neuroprotective activity at 50-100 μM in dopaminergic-differentiated SH-SY5Y cells. Additionally, Pro-to-Nic substitution showed no cytotoxicity in HepG2, reduced P-glycoprotein-mediated efflux, and preserved β-turn conformational propensity, supporting improved oral drug-like properties. Collectively, these findings identify 6c as a dual-acting lead and establish Nic as a privileged Pro surrogate for next-generation MIF-1-based PD therapeutics.

MeSH

Msh Release-Inhibiting Hormone, Niacinamide, Vitamins, Pharmaceutical Preparations, Dopamine, Neuropeptides, Therapeutics